Valuation: Biomea Fusion, Inc.

Market Cap 42.2M 38.24M 35.37M 31.91M 60.14M 3.98B 62.26M 425M 168M 2.13B 158M 155M 6.75B P/E 2026 *
-0.9x
P/E 2027 * -0.84x
Enterprise Value 42.2M 38.24M 35.37M 31.91M 60.14M 3.98B 62.26M 425M 168M 2.13B 158M 155M 6.75B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Biomea Fusion, Inc.

1 day+3.47%
1 week+2.72%
Current month-8.96%
1 month-30.19%
3 months-55.89%
6 months-59.29%
Current year-53.05%
1 week 0.54
Extreme 0.5401
0.63
1 month 0.54
Extreme 0.5401
0.97
Current year 0.54
Extreme 0.5401
2.24
1 year 0.54
Extreme 0.5401
2.24
3 years 0.54
Extreme 0.5401
22.74
5 years 0.54
Extreme 0.5401
43.69
10 years 0.54
Extreme 0.5401
43.69
Manager TitleAgeSince
President 62 2017-07-31
Chief Executive Officer 76 2025-03-24
Chief Tech/Sci/R&D Officer - 2020-07-31
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 76 2021-02-28
Director/Board Member 62 2017-07-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/10/26 Free

Director

196,299 0.2759%
4/1/26 Free

Founder

452,512 0.6360%
4/1/26 Free

Chief Executive Officer

667,477 0.9381%
Change 5-day change 1-year change 3-year change Capi.($)
+3.47%+2.72%-54.52%-93.45% 42.2M
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.21%+0.32%+27.66%+152.78% 41B
Weighted average by Cap. -0.83%+0.20%+36.62%+155.22%

Financials

2026 *2027 *
Net sales - -
Net income -48.1M -43.59M -40.32M -36.38M -68.55M -4.54B -70.97M -484M -192M -2.42B -181M -177M -7.69B -68.52M -62.09M -57.43M -51.82M -97.65M -6.46B -101M -690M -274M -3.45B -257M -252M -10.96B
Net Debt - -
Projected Income Statement - Annual - Biomea Fusion, Inc.
Logo Biomea Fusion, Inc.
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies, including icovamenib and BMF-650, for diabetes and obesity, with research activities focused on the biology of metabolic diseases. Its covalent small molecule drug is a synthetic compound that forms a permanent bond with its target protein. The Company’s clinical candidate, icovamenib, is an investigational oral small molecule that reversibly downmodulates menin, a transcriptional regulator involved in beta-cell biology. Its Phase 2 clinical development includes type 1 and type 2 diabetes, obesity, and combination with GLP-1 receptor agonist therapies. The Company’s second product candidate, BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for the treatment of diabetes and obesity.
Employees
37
Date Price Change Volume
26-11-13 US$0.5822 +3.47% 563,879
26-11-12 US$0.5627 -7.89% 839,262
26-11-11 US$0.6109 +11.68% 694,711
26-11-10 US$0.5470 -8.07% 896,303
26-11-09 US$0.5950 +4.98% 737,129
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Biomea Fusion, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.5822USD
Average target price
6.167USD
Spread / Average Target
+959.20%
  1. Stock Market
  2. Stocks
  3. BMEA Stock